Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue
+4.59%
EPS
−28.0%
Free cash flow
+202.4%
Total debt
−42.2%

Quarter to September 2026, against a year earlier

72.79 0.13 +0.18%
Market cap
$11.4B
P/E
66.2×
Fwd P/E
54.2×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100

Bio-Techne Corp 8-K filed Feb 5, 2025

Period ended Jan 30, 2025 · Filed · accepted 6:30 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release